Blog

New FDA guidance: cell therapies and patient identifiers
When the US Food and Drug Administration (FDA) recently made two draft guidance documents for the cell and gene therapies available for comment, the Vineti team was quick to scan for one three-letter phrase that is core to our mission – COI.
Cybersecurity challenges in advanced therapies — introducing five strategies for success
Pharmaceutical and biotech companies suffer more security breaches than any other industry1 — with greater than 20% of companies in the pharmaceutical sector having been…
Lykan Bioscience and Vineti Announce Partnership to Advance Cell-based Therapies from Clinical to Commercialization
Lykan Bioscience’s world-class manufacturing capabilities, integrated with Vineti’s leading digital enterprise platform for cell and gene therapy supply chains, will streamline process development and manufacturing…
Vineti announces agreement with Imvax to utilize Vineti’s PTM Essentials™ solution
Vineti’s enterprise technology will enable critical patient-specific Chain of Custody management for Imvax, supporting Imvax’s goal of reaching more patients as fast as possible
Building CGT’s Clinical Trial Potential: PRA’s Partnership with Cell and Gene Therapy Supply Chain Software Leader Vineti
Key Highlights: PRA’s partnership with Vineti will optimize clinical trial delivery, clinical study operations and data management, and commercialization readiness...
PRA Health Sciences Announces Partnership with Vineti
RALEIGH, NC and SAN FRANCISCO, CA, June 15, 2021 — PRA Health Sciences and Vineti, Inc., today announced a new...
Ori Biotech and Vineti Form Strategic Partnership to Deliver Integrated Manufacturing and Supply Chain Solutions for Cell and Gene Therapies
Platform integration will provide therapy developers with full end-to-end visibility, control, and insights into manufacturing and supply chain LONDON and...
Vineti Introduces PTM Essentials™ to Accelerate Cell and Gene Therapy Clinical Trials with a New Digital Supply Chain Solution
New PTM Essentials™ solution draws on Vineti’s industry-leading Personalized Therapy Management® (PTM) software platform to deliver breakthrough speed and simplicity for advanced...
Advanced Therapies Guide – seven key challenges and proven solutions – in advanced therapy clinical trials
Advanced therapies emerge from advanced science — and must overcome the operational complexity inherent in their patient-centric paradigm when they...
A new Five-minute Guide — seven key challenges in advanced therapy clinical trials
Advanced therapies emerge from advanced science — and must overcome the operational complexity inherent in their patient-centric paradigm when they...
Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies
Genentech, Takeda, Adaptimmune and other industry leaders join Vineti to form the core of this strategic collaboration. The group is...
Repost: a modern patient ID for personalized medicine
Today, Vineti released an announcement about new industry collaboration around our proposal for a new patient ID for cell and gene therapies....
A fresh start for advanced therapy clinical trials
A look at 2020 and the coming rebound, by the numbers Even before the unpredictable year that was 2020, one...